CSL agrees to develop rare-disease drug with Alentis
Published on 10/10/2026 at 10:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- CSL agreed to co-develop and co-promote lixudebart with Alentis.
- The agreement includes a US$355 million initial payment and up to US$1.2 billion in commercial milestones.
- CSL Limited closed at AUD 183.84 on October 9, 2026, according to structured finance data.
CSL and Alentis Therapeutics announced on October 5, 2026, that they had entered an exclusive global collaboration to co-develop and co-promote lixudebart for kidney, liver and other diseases. The announcement was published by CSL’s newsroom.
CSL will make an initial payment of US$355 million to Alentis, which may receive up to an additional US$1.2 billion in commercial milestone payments. CSL will fully fund the ongoing Phase 2 RENAL trial, planned Phase 3 work in ANCA-associated vasculitis with rapidly progressive glomerulonephritis, and Phase 2 trials in focal segmental glomerulosclerosis and primary sclerosing cholangitis.
The partnership
Lixudebart is being evaluated in the Phase 2 RENAL trial. Under the agreement, CSL and Alentis will jointly develop and co-promote the therapy. If commercialized, global profits will be shared 55 percent by CSL and 45 percent by Alentis.
CSL Limited’s structured finance quote for October 9, 2026, showed a closing price of AUD 183.84, compared with a previous close of AUD 181.46. The quote was timestamped October 9, 2026, at 7:12 a.m. CEST after conversion from the source’s UTC timestamp.
Market context: Market report S&P/ASX 200.
Company development
CSL said the collaboration is intended to combine Alentis’ claudin-1 expertise with CSL’s development and commercialization capabilities in nephrology. Lixudebart is an investigational monoclonal antibody targeting exposed claudin-1.
